An interventional study of CG-100 Intraluminal Bypass Device in Colorectal Cancer, sponsored by Colospan Ltd.. Completed at 1 site in Israel. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Colospan Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Colorectal Neoplasms with a site in Israel — 13 open to participants now, 22 under way, 5 of them phase 3. Colorectal Neoplasms · Israel.
Among the 89 studies in Colorectal Neoplasms with a site in Israel, this one is the 76th largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 with no phase, and was the 75th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →13 of the 89 studies in Colorectal Neoplasms with a site in Israel are open now. Recruiting first, the newest first:
Pfizer · Sites in Israel, United States, Argentina and 17 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Israel, United States, Canada and 4 more countries
Ages 18+
HepaRegeniX GmbH · Sites in Israel, United States, France and 2 more countries
Ages 18–75
AbbVie · Sites in Israel, United States, Australia and 12 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Israel, United States, Australia and 23 more countries
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 22 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 26 · Phase 3 26 · Phase 4 1
First in 1993; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 302 across the 78 interventional studies, 160 across the 9 observational. Of the 57 that completed or were terminated, 27 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
Colospan Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Colospan Ltd. has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Colorectal Neoplasms with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
| NCT03919461Assaf-Harofeh Medical CenterColorectal Metastasis Prevention International Trial 2 | 2027-02-28 |
| NCT03821935AbbVieStudy to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | 2027-06 |
| NCT06638502HepaRegeniX GmbHSafety of HRX215 in Patients After Minor and Major Liver Resection | 2027-07-31 |
| NCT06614192AbbVieA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | 2027-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 89 studies in Colorectal Neoplasms with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of CG-100 Intraluminal Bypass device
Inclusion Criteria (pre-operative):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be treated with CG-100 Intraluminal Bypass Device
Device: CG-100 Intraluminal Bypass Device
Subjects will be treated with the CG-100 Intraluminal Bypass Device
Safety of the CG-100 Intraluminal Bypass Device
Assessment of Serious Adverse Events
Time frame: 10 days
Safety of the CG-100 Intraluminal Bypass Device
Assessment of Serious Adverse Events
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Apr 2024, 13 months.
Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 13 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colospan Ltd.